Generics BulletinFresenius Kabi is set to enjoy a 14-year jump on the US patents shielding Pacira BioSciences’ Exparel (bupivacaine) liposomal injectable, albeit with a volume limit that will last for nearly a decade,
Generics BulletinFresenius Kabi will look to launch its denosumab biosimilars to Prolia and Xgeva in the US in mid-2025, after the German firm received US Food and Drug Administration approval for the biosimilars – th
Generics BulletinPierluigi Antonelli was less than three months into his role as a member of the Management Board of Fresenius, responsible for the group’s operating company Fresenius Kabi, when he recognised an eye
Pink SheetThe six biosimilars to Johnson & Johnson ’s Stelara that have launched in the US have list prices 80% to 90% below the innovator’s wholesale acquisition cost, representing deeper discounts than t